Search

Your search keyword '"Giralt, S."' showing total 70 results
Start Over Author "Giralt, S." Database OpenAIRE
70 results on '"Giralt, S."'

1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Author

Costa, L.J. Derman, B.A. Bal, S. Sidana, S. Chhabra, S. Silbermann, R. Ye, J.C. Cook, G. Cornell, R.F. Holstein, S.A. Shi, Q. Omel, J. Callander, N.S. Chng, W.J. Hungria, V. Maiolino, A. Stadtmauer, E. Giralt, S. Pasquini, M. Jakubowiak, A.J. Morgan, G.J. Krishnan, A. Jackson, G.H. Mohty, M. Mateos, M.V. Dimopoulos, M.A. Facon, T. Spencer, A. Miguel, J.S. Hari, P. Usmani, S.Z. Manier, S. McCarthy, P. Kumar, S. Gay, F. Paiva, B.

Subjects
body regions, hemic and lymphatic diseases
Abstract

Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy. There is substantial heterogeneity across clinical trials in how MRD is assessed and reported, creating challenges for data interpretation and for the design of subsequent studies. We convened an international panel of MM investigators to harmonize how MRD should be assessed and reported in MM clinical trials. The panel provides consensus on which MM trials should include MRD, the recommended time points for MRD assessment, and expected analytical validation for MRD assays. We subsequently outlined parameters for reporting MRD results implementing the intention-to-treat principle. The panel provides guidance regarding the incorporation of newer peripheral blood-based and imaging-based approaches to detection of residual disease. Recommendations are summarized in 13 consensus statements that should be followed by sponsors, investigators, editors, and reviewers engaged in designing, performing, and interpreting MM trials. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.

Published
2021

2. CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age 50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Author

Barba, P, Martino, R, Zhou, Q, Cho, C, Castro-Malaspina, H, Devlin, S, Esquirol, A, Giralt, S, Jakubowski, AA, Caballero, D, Maloy, M, Papadopoulos, EB, Pifiana, JL, Fox, ML, Marquez-Malaver, FJ, Valcarcel, D, Solano, C, Lopez-Corral, L, Sierra, J, and Perales, MA

Subjects
surgical procedures, operative, hemic and lymphatic diseases, RIC, GVHD, Allogeneic hematopoietic cell transplantation, T cell depletion
Abstract

Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34 cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). To compare the efficacy of the RIC and TCD approaches, we evaluated the outcomes of patients age >50 years with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable in the patients receiving TCD (n = 204). and those receiving RIC (n = 151), except for a higher proportion of unrelated donors (68% versus 40%; P 50 years with AML and MDS. (C) 2017 American Society for Blood and Marrow Transplantation.

Published
2018

3. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

Author

Dimopoulos, M.A. Sonneveld, P. Leung, N. Merlini, G. Ludwig, H. Kastritis, E. Goldschmidt, H. Joshua, D. Orlowski, R.Z. Powles, R. Vesole, D.H. Garderet, L. Einsele, H. Palumbo, A. Cavo, M. Richardson, P.G. Moreau, P. Miguel, J.S. Vincent Rajkumar, S. Durie, B.G.M. Terpos, E. Abildgaard, N. Abonour, R. Alsina, M. Anderson, K.C. Attal, M. Avet-Loiseau, H. Badros, A. Bahlis, N.J. Barlogie, B. Bataille, R. Beksaç, M. Belch, A. Ben-Yehuda, D. Bensinger, B. Leif Bergsagel, P. Bhutani, M. Bird, J. Bladé, J. Broijl, A. Boccadoro, M. Caers, J. Chanan-Khan, A. Chari, A. Chen, W.M. Chesi, M. Anthony Child, J. Chim, C.S. Chng, W.-J. Comenzo, R. Cook, G. Crowley, J. Crusoe, E. Dalton, W. Lee Moffitt, H. Davies, F. de la Rubia, J. de Souza, C. Delforge, M. Dhodapkar, M. Dispenzieri, A. Drach, J. Drake, M. Du, J. Dytfeld, D. Facon, T. Fantl, D. Fermand, J.-P. Fernández de Larrea, C. Fonseca, R. Gahrton, G. Garćia-Sanz, R. Gasparetto, C. Gertz, M. Ghobrial, I. Gibson, J. Gimsing, P. Giralt, S. Gu, J. Hajek, R. Hardan, I. Hari, P. Hata, H. Hattori, Y. Heffner, T. Hillengass, J. Ho, J. Hoering, A. Hoffman, J.E. Hou, J. Huang, J. Hungria, V. Ida, S. Jagannath, S. Jakubowiak, A.J. Johnsen, H.E. Jurczyszyn, A. Kaiser, M. Kaufman, J. Kawano, M. Korde, N. Kovacs, E. Krishnan, A. Kristinsson, S. Kröger, N. Kumar, S. Kyle, R.A. Kyriacou, C. Lacy, M. Lahuerta, J.J. Landgren, O. Larocca, A. Laubach, J. da Costa, F.L. Lee, J.-H. Leiba, M. Leleu, X. Lentzsch, S. Lokhorst, H. Lonial, S. Lu, J. Mahindra, A. Maiolino, A. Manasanch, E.E. Mark, T. Mateos, M.-V. Mazumder, A. McCarthy, P. Mehta, J. Mellqvist, U.-H. Mikhael, J. Morgan, G. Munshi, N. Nahi, H. Nawarawong, W. Niesvizky, R. Nouel, A. Novis, Y. Ocio, E. O'Dwyer, M. O'Gorman, P. Orfao, A. Otero, P.R. Paiva, B. Pavlovsky, S. Pilarski, L. Pratt, G. Qui, L. Raje, N. Reece, D. Reiman, A. Remaggi, G. Richter, J. Serra, E.R. Morales, A.R. Romeril, K.R. Roodman, D. Rosiñol, L. Rossi, A. Roussel, M. Russell, S. Schjesvold, F. Schots, R. Sevcikova, S. Sezer, O. Shah, J.J. Shimizu, K. Shustik, C. Siegel, D. Singhal, S. Spencer, A. Stadtmauer, E. Stewart, K. Tan, D. Terragna, C. Tosi, P. Tricot, G. Turesson, I. Usmani, S. Van Camp, B. Van de Donk, N. Van Ness, B. Van Riet, I. Broek, I.V. Vanderkerken, K. Vescio, R. Vij, R. Voorhees, P. Waage, A. Wang, M. Weber, D. Weiss, B.M. Westin, J. Wheatley, K. Zamagni, E. Zonder, J. Zweegman, S.

Abstract

Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A). © 2016 by American Society of Clinical Oncology.

Published
2016

4. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Author

Giralt, S. Garderet, L. Durie, B. Cook, G. Gahrton, G. Bruno, B. Hari, P. Lokhorst, H. McCarthy, P. Krishnan, A. Sonneveld, P. Goldschmidt, H. Jagannath, S. Barlogie, B. Mateos, M. Gimsing, P. Sezer, O. Mikhael, J. Lu, J. Dimopoulos, M. Mazumder, A. Palumbo, A. Abonour, R. Anderson, K. Attal, M. Blade, J. Bird, J. Cavo, M. Comenzo, R. de la Rubia, J. Einsele, H. Garcia-Sanz, R. Hillengass, J. Holstein, S. Johnsen, H.E. Joshua, D. Koehne, G. Kumar, S. Kyle, R. Leleu, X. Lonial, S. Ludwig, H. Nahi, H. Nooka, A. Orlowski, R. Rajkumar, V. Reiman, A. Richardson, P. Riva, E. San Miguel, J. Turreson, I. Usmani, S. Vesole, D. Bensinger, W. Qazilbash, M. Efebera, Y. Mohty, M. Gasparreto, C. Gajewski, J. LeMaistre, C.F. Bredeson, C. Moreau, P. Pasquini, M. Kroeger, N. Stadtmauer, E.

Subjects
surgical procedures, operative, immune system diseases, hemic and lymphatic diseases
Abstract

In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward. After reviewing the available data, the expert committee came to the following consensus statement for salvage autologous HCT: (1) In transplantation-eligible patients relapsing after primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard; (2) High-dose therapy and autologous HCT should be considered appropriate therapy for any patients relapsing after primary therapy that includes an autologous HCT with initial remission duration of more than 18 months; (3) High-dose therapy and autologous HCT can be used as a bridging strategy to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in the context of well-designed prospective trials that should include new agents, such as monoclonal antibodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous HCT consolidation should be explored as a strategy to develop novel conditioning regimens or post-HCT strategies in patients with short (less than 18 months remissions) after primary therapy; and (6) Prospective randomized trials need to be performed to define the role of salvage autologous HCT in patients with MM relapsing after primary therapy comparing it to "best non-HCT" therapy. The expert committee also underscored the importance of collecting enough hematopoietic stem cells to perform 2 transplantations early in the course of the disease. Regarding allogeneic HCT, the expert committee agreed on the following consensus statements: (1) Allogeneic HCT should be considered appropriate therapy for any eligible patient with early relapse (less than 24 months) after primary therapy that included an autologous HCT and/or high-risk features (ie, cytogenetics, extramedullary disease, plasma cell leukemia, or high lactate dehydrogenase); (2) Allogeneic HCT should be performed in the context of a clinical trial if possible; (3) The role of postallogeneic HCT maintenance therapy needs to be explored in the context of well-designed prospective trials; and (4) Prospective randomized trials need to be performed to define the role salvage allogeneic HCT in patients with MM relapsing after primary therapy. © 2015 American Society for Blood and Marrow Transplantation.

Published
2015

5. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib:A multicenter international myeloma working group study

Author

Kumar S. K., Lee J. H., Lahuerta J. J., Morgan G., Richardson P. G., Crowley J., Haessler J., Feather J., Hoering A., Moreau P., LeLeu X., Hulin C., Klein S. K., Sonneveld P., Siegel D., Bladé J., Goldschmidt H., Jagannath S., Miguel J. S., Orlowski R., Palumbo A., Sezer O., Rajkumar S. V., Durie B. G. International Myeloma Working Group Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben Yehuda D, Bensinger B, Bergsagel PL, Bird J, Bladé J, Boccadoro M, Chanan Khan A, Chen WM, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen HE, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nahi H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Rajkumar SV, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, San Miguel J, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Vande Broek I, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J., CAVO, MICHELE, Kumar S.K., Lee J.H., Lahuerta J.J., Morgan G., Richardson P.G., Crowley J., Haessler J., Feather J., Hoering A., Moreau P., LeLeu X., Hulin C., Klein S.K., Sonneveld P., Siegel D., Bladé J., Goldschmidt H., Jagannath S., Miguel J.S., Orlowski R., Palumbo A., Sezer O., Rajkumar S.V., Durie B.G. International Myeloma Working Group Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Bergsagel PL, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Chen WM, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen HE, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nahi H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Rajkumar SV, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, San Miguel J, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Vande Broek I, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J., and Hematology

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, NATURAL HISTORY, Antineoplastic Agents, Context (language use), RELAPSE, Article, Recurrence, Internal medicine, medicine, Humans, Immunologic Factors, Elotuzumab, Survival analysis, Multiple myeloma, Aged, Aged, 80 and over, Isatuximab, Bortezomib, business.industry, Hematology, Middle Aged, Pomalidomide, medicine.disease, Survival Analysis, Surgery, Regimen, SURVIVAL, Disease Progression, Female, Multiple Myeloma, business, medicine.drug
Abstract

Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T-0). The median age at diagnosis was 58 years, and time from diagnosis to T-0 was 3.3 years. Following T-0, 213 (74%) patients had a treatment recorded with one or more regimens (median = 1; range 0-8). The first regimen contained bortezomib in 55 (26%) patients and an IMiD in 70 (33%). A minor response or better was seen to at least one therapy after T0 in 94 patients (44%) including >= partial response in 69 (32%). The median overall survival and event-free survival from T-0 were 9 and 5 months, respectively. This study confirms the poor outcome, once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs. Leukemia (2012) 26, 149-157; doi:10.1038/leu.2011.196; published online 29 July 2011

Published
2012

6. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

Author

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG, IMWG, TOSI, PATRIZIA, CAVO, MICHELE, Radiology & Nuclear Medicine, Hematology, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG, and IMWG.

Subjects
Oncology, Benzylamines, Cancer Research, medicine.medical_specialty, Anti-HIV Agents, medicine.medical_treatment, Context (language use), Hematopoietic stem cell transplantation, Cyclams, Transplantation, Autologous, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Heterocyclic Compounds, Internal medicine, medicine, Humans, Autologous transplantation, Multiple myeloma, business.industry, Plerixafor, Hematopoietic Stem Cell Transplantation, Hematology, medicine.disease, Hematopoietic Stem Cell Mobilization, 3. Good health, Transplantation, 030220 oncology & carcinogenesis, Immunology, Blood Component Removal, Stem cell, Multiple Myeloma, business, 030215 immunology, medicine.drug
Abstract

Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.

Published
2009

7. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Author

Kumar, S, Giralt, S, Stadtmauer, Ea, Harousseau, Jl, Palumbo, Antonio, Bensinger, W, Comenzo, Rl, Lentzsch, S, Munshi, N, Niesvizky, R, San Miguel, J, Ludwig, H, Bergsagel, L, Blade, J, Lonial, S, Anderson, Kc, Tosi, P, Sonneveld, P, Sezer, O, Vesole, D, Cavo, M, Einsele, H, Richardson, Pg, Durie, Bg, Rajkumar, Sv, International Myeloma Working Group, Radiology & Nuclear Medicine, Hematology, Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV, and International Myeloma Working Group.

Subjects
Oncology, medicine.medical_specialty, Consensus Development Conferences as Topic, medicine.medical_treatment, Immunology, Antineoplastic Agents, Hematopoietic stem cell transplantation, Medical Oncology, Biochemistry, Bortezomib, Autologous stem-cell transplantation, Internal medicine, medicine, Humans, Lenalidomide, Multiple myeloma, Hematopoietic Stem Cell Mobilization, Clinical Trials as Topic, business.industry, Hematopoietic Stem Cell Transplantation, Cell Biology, Hematology, medicine.disease, Boronic Acids, Combined Modality Therapy, Thalidomide, Pyrazines, Stem cell, Multiple Myeloma, business, Immunosuppressive Agents, medicine.drug
Abstract

The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization. (Blood. 2009;114:1729-1735)

Published
2009

8. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

Author

Hussein M. A., Vrionis F. D., Allison R., Berenson J., Berven S., Erdem E., Giralt S., Jagannath S., Kyle R. A., LeGrand S., Pflugmacher R., Raje N., Rajkumar S. V., Randall R. L., Roodman D., Siegel D., Vescio R., Zonder J., Durie B. G., International Myeloma Working Group, Cavo M, Hussein M.A., Vrionis F.D., Allison R., Berenson J., Berven S., Erdem E., Giralt S., Jagannath S., Kyle R.A., LeGrand S., Pflugmacher R., Raje N., Rajkumar S.V., Randall R.L., Roodman D., Siegel D., Vescio R., Zonder J., Durie B.G., International Myeloma Working Group [.., Cavo M, ], Faculty of Law and Criminology, and Private and Economic Law

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Consensus, Polymethyl methacrylate, Statement (logic), health care facilities, manpower, and services, education, Multiple Myeloma/complications, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Lymphoid neoplasms, health care economics and organizations, Multiple myeloma, Hematology, business.industry, medicine.disease, B-cell neoplasm, Surgery, minimally invasive surgical procedures, Spinal Fractures/complications, oncology, business, Polymethyl Methacrylate/administration & dosage
Abstract

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

Published
2008

9. Interacción entre clima y ocupación humana en la configuración del paisaje vegetal del Parque Nacional de Aigüestortes i Estany de Sant Maurici a lo largo de los últimos 15.000 años

Author

Catalan, J, Pèlachs, A, Gassiot, E, Antolín, F, Ballesteros, A, Batalla, M, Burjachs, F, Buchaca, T, Camarero, L, Clemente, I, Clop, X, García, D, Giralt, S, Lluch, Lj, Madella, M, Mazzucco, N, Mur, E, Ninyerola, M, Obea, L, Oltra, J, Pérez-Obiol, R, Piqué, R, Pla-Rabés, S, Rondón, S, Rodríguez, Jm, Rodríguez-Anton, D, Sáez, A, and Soriano, Jm

Subjects
high mountain landscape, Past climate, Late Glacial, Holocene, vegetation, Past climate, vegetation, past human impact, high mountain landscape, Holocene, Late Glacial, past human impact, Late Glacialardig
Abstract

The vegetation of the National Park of Aigüestortes i Estany de St Maurici is the result of an interaction between climate, plant community dynamics and the human occupation of the territory. The OCUPA project aimed to reconstruct this interaction across the last millennia combining methods from palaeoecology and archaeology. The study focused primarily on the Sant Nicolau valley and built on the multidisciplinary analysis of the sedimentary archive of two lakes (Llebreta and Redó) and a number of archaeological sites located in shelters and outdoors. There is archaeological evidence of human presence since 9000 yr cal BP, and a continuous record since 7500 yr cal BP. At early stages, humans transformed the surroundings of the shelters occupied and lithic tools indicate contacts with locations far away (i.e., the Ebro plains). Since more than 3000 years ago, there has been human impact on the vegetation without interruption until present. Initially, the impacts were mostly related to livestock: use of fire to open grazing lands, soil erosion and, during the medieval period, forestry and eutrophication of lakes. The agriculture impact in the lower part of the valley (e.g., Llebreta) occurred about 2100 yr ago, although some cereal grains and tools for harvesting have been found for the Neolithic. In the medieval period, the impact was higher than during the last centuries. In general, the changes in the human land use approximately follow the major changes in climate, but the specific causal link is likely related to the social and cultural dynamics of a broader territory since the Neolithic., Para el sondeo y estudio mineralógico se ha contado con la colaboración de financiación adicional a través del proyecto «Multidisciplinary research consortium on gradual and abrupt climate changes, and their impacts on the environment (GRACCIE), CSD2007-00067, Programa Consolider 2007»

Published
2013

10. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib

Author

Kumar, Sk, Lee, Jh, Lahuerta, Jj, Morgan, G, Richardson, Pg, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, Leleu, X, Hulin, C, Klein, Sk, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, Js, Orlowski, R, Palumbo, Antonio, Sezer, O, Rajkumar, Sv, Durie, Bg, on behalf of the International Myeloma Working Group, International Myeloma Working Group, Abildgaard, N, Abonour, R, Alexanian, R, Alsina, M, Anderson, Kc, Attal, M, Avet Loiseau, H, Badros, A, Baris, D, Barlogie, B, Bataille, R, Beksaç, M, Belch, A, Ben Yehuda, D, Bensinger, B, Leif Bergsagel, P, Bird, J, Boccadoro, M, Cavo, M, Chanan Khan, A, Ming Chen, W, Child, T, Chim, J, Chng, Wj, Comenzo, R, Dalton, W, Davies, F, de Souza, C, Delforge, M, Dimopoulos, M, Dispenzieri, A, Drach, J, Drake, M, Einsele, H, Facon, T, Fantl, D, Fermand, Jp, Fonseca, R, Gahrton, G, García Sanz, R, Gasparetto, C, Gertz, M, Gibson, J, Giralt, S, Greipp, P, Hajek, R, Hardan, I, Hari, P, Harousseau, Jl, Hata, H, Hattori, Y, Heffner, T, Ho, J, Hungria, V, Ida, S, Jacobs, P, Johnsen, H, Jian, H, Joshua, D, Jurczyszyn, A, Kawano, M, Kröger, N, Kumar, S, Kyle, Ra, Lacy, M, Landgren, O, Laubach, J, Lentzsch, S, Lokhorst, H, Lonial, S, Ludwig, H, Maiolino, A, Mateos, M, Mehta, J, Mellqvist, Uh, Merlini, G, Mikhael, J, Morales, Ar, Nari, H, Munshi, N, Niesvizky, R, Nouel, A, Novis, Y, Palumbo, A, Pavlovsky, S, Pilarski, L, Powles, R, Raje, N, Vincent Rajkumar, S, Reece, D, Reiman, T, Roodman, D, Rosiñol, L, Shah, Jj, Shaughnessy, J, Shimizu, K, Shustik, C, Singhal, S, Spencer, A, Stadtmauer, E, Stewart, K, Terpos, E, Tosi, P, Tricot, G, Turesson, I, Van Camp, B, Van Ness, B, Van Riet, I, Broek, Iv, Vanderkerken, K, Vescio, R, Vesole, D, Waage, A, Wang, M, Weber, D, Westin, J, Wheatley, K, and Zonder, J.

Published
2012

11. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

Author

Dimopoulos, M. Kyle, R. Fermand, J.-P. Rajkumar, S.V. San Miguel, J. Chanan-Khan, A. Ludwig, H. Joshua, D. Mehta, J. Gertz, M. Avet-Loiseau, H. Beksaç, M. Anderson, K.C. Moreau, P. Singhal, S. Goldschmidt, H. Boccadoro, M. Kumar, S. Giralt, S. Munshi, N.C. Jagannath, S.

Abstract

A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β2-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse. © 2011 by The American Society of Hematology.

Published
2011

13. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Author

Kumar, Sk, Lee, Jh, Lahuerta, Jj, Morgan, G, Richardson, Pg, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, Leleu, X, Hulin, C, Klein, Sk, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, Js, Orlowski, R, Palumbo, Antonio, Sezer, O, Rajkumar, Sv, Durie, Bg, on behalf of the International Myeloma Working Group, International Myeloma Working Group, Abildgaard, N, Abonour, R, Alexanian, R, Alsina, M, Anderson, Kc, Attal, M, Avet Loiseau, H, Badros, A, Baris, D, Barlogie, B, Bataille, R, Beksaç, M, Belch, A, Ben Yehuda, D, Bensinger, B, Leif Bergsagel, P, Bird, J, Boccadoro, M, Cavo, M, Chanan Khan, A, Ming Chen, W, Child, T, Chim, J, Chng, Wj, Comenzo, R, Dalton, W, Davies, F, de Souza, C, Delforge, M, Dimopoulos, M, Dispenzieri, A, Drach, J, Drake, M, Einsele, H, Facon, T, Fantl, D, Fermand, Jp, Fonseca, R, Gahrton, G, García Sanz, R, Gasparetto, C, Gertz, M, Gibson, J, Giralt, S, Greipp, P, Hajek, R, Hardan, I, Hari, P, Harousseau, Jl, Hata, H, Hattori, Y, Heffner, T, Ho, J, Hungria, V, Ida, S, Jacobs, P, Johnsen, H, Jian, H, Joshua, D, Jurczyszyn, A, Kawano, M, Kröger, N, Kumar, S, Kyle, Ra, Lacy, M, Landgren, O, Laubach, J, Lentzsch, S, Lokhorst, H, Lonial, S, Ludwig, H, Maiolino, A, Mateos, M, Mehta, J, Mellqvist, Uh, Merlini, G, Mikhael, J, Morales, Ar, Nari, H, Munshi, N, Niesvizky, R, Nouel, A, Novis, Y, Palumbo, A, Pavlovsky, S, Pilarski, L, Powles, R, Raje, N, Vincent Rajkumar, S, Reece, D, Reiman, T, Roodman, D, Rosiñol, L, Shah, Jj, Shaughnessy, J, Shimizu, K, Shustik, C, Singhal, S, Spencer, A, Stadtmauer, E, Stewart, K, Terpos, E, Tosi, P, Tricot, G, Turesson, I, Van Camp, B, Van Ness, B, Van Riet, I, Broek, Iv, Vanderkerken, K, Vescio, R, Vesole, D, Waage, A, Wang, M, Weber, D, Westin, J, Wheatley, K, and Zonder, J.

Published
2011

15. Evolució del paisatge vegetal al Camp de Tarragona: estudi pol·línic de la seqüència sedimentològica procedent de l'aiguamoll de la Sèquia Major (la Pineda, Vila-seca)

Author

Riera, Santiago, Miras, Yannick, Giralt, S., Servera Vives, Gabriel, SERP, Universitat de Barcelona (UB), Laboratoire de Géographie Physique et Environnementale (GEOLAB), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut Sciences de l'Homme et de la Société (IR SHS UNILIM), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), université de Barcelone, Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Université Clermont Auvergne (UCA)-Institut Sciences de l'Homme et de la Société (IR SHS UNILIM), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Centre National de la Recherche Scientifique (CNRS), Institute of Earth Sciences Jaume Almera, Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Marta Prevosti i Josep Guitart i Duran, Miras, Yannick, Servera Vives, Gabriel, and Université de Barcelonne

Subjects
[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistory, [SHS.ARCHEO]Humanities and Social Sciences/Archaeology and Prehistory, [SDE.ES] Environmental Sciences/Environmental and Society, Sedimentology, [SDE.ES]Environmental Sciences/Environmental and Society, Palinologia, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

16. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Author

Palumbo, A., Sezer, Orthan, Kyle, Robert, San Miguel, Jésus F., Orlowski, Rz, Moreau, Philippe, Niesvizky, R., Morgan, G, Comenzo, R, Sonneveld, Pieter, Kumar, Sk, Hajek, R., Giralt, S, Van Riet, Ivan, and Hematology

Subjects
myeloma
Abstract

In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous stem cell transplantation. Here we present recommendations on the diagnosis, treatment of newly diagnosed non-transplant-eligible patients and the management of complications occurring during induction therapy among these patients. These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM.

Published
2009

17. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

Author

Giralt, S, Stadtmauer, Ea, Harousseau, J.l., Palumbo, A., Bensinger, W, Comenzo, R, Kumar, Sk, Munshi, Nc, Dispenzieri, A, Kyle, Robert, Merlini, G, San Miguel, Jésus F., Van Riet, Ivan, and Hematology

Subjects
myeloma
Abstract

Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.

Published
2009

18. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

Author

Giralt, S. Stadtmauer, E. A. Harousseau, J. L. Palumbo, A. and Bensinger, W. Comenzo, R. L. Kumar, S. Munshi, N. C. and Dispenzieri, A. Kyle, R. Merlini, G. San Miguel, J. and Ludwig, H. Hajek, R. Jagannath, S. Blade, J. Lonial, S. and Dimopoulos, M. A. Einsele, H. Barlogie, B. Anderson, K. C. Gertz, M. Attal, M. Tosi, P. Sonneveld, P. and Boccadoro, M. Morgan, G. Sezer, O. Mateos, M. V. Cavo, M. Joshua, D. Turesson, I. Chen, W. Shimizu, K. and Powles, R. Richardson, P. G. Niesvizky, R. Rajkumar, S. V. and Durie, B. G. M. IMWG

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions. Leukemia (2009) 23, 1904-1912; doi: 10.1038/leu.2009.127; published online 25 June 2009

Published
2009

19. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Author

Palumbo, A. Sezer, O. Kyle, R. Miguel, J. S. Orlowski, R. Z. Moreau, P. Niesvizky, R. Morgan, G. Comenzo, R. and Sonneveld, P. Kumar, S. Hajek, R. Giralt, S. and Bringhen, S. Anderson, K. C. Richardson, P. G. Cavo, M. and Davies, F. Blade, J. Einsele, H. Dimopoulos, M. A. and Spencer, A. Dispenzieri, A. Reiman, T. Shimizu, K. Lee, J. H. Attal, M. Boccadoro, M. Mateos, M. Chen, W. and Ludwig, H. Joshua, D. Chim, J. Hungria, V. Turesson, I. and Durie, B. G. M. Lonial, S. IMWG

Abstract

In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous stem cell transplantation. Here we present recommendations on the diagnosis, treatment of newly diagnosed non-transplant-eligible patients and the management of complications occurring during induction therapy among these patients. These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM. Leukemia (2009) 23, 1716-1730; doi: 10.1038/leu.2009.122; published online 4 June 2009

Published
2009

20. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursorsCD34+ cells phenotype in myelodysplastic syndromes

Author

Matarraz, Sergio, López, Antonio, Barrena, Susana, Fernández, Carlos, Jensen, Evan, Flores-Montero, Juan, Bárcena, Paloma, Rasillo, Ana, Sayagués, José María, Hernández-Campo, Pilar M., Giralt, S., and Orfao, Alberto

Subjects
hemic and lymphatic diseases
Abstract

Occurrence of phenotypic abnormalities in CD34+ hematopoietic progenitor and precursor cells (HPC) and their major B-cell and nonlymphoid compartments has been frequently reported in myelodysplastic syndromes (MDS). Here, we analyze for the first time the numerical and phenotypic abnormalities of different maturation-associated subsets of bone marrow (BM) CD34+ HPC from 50 newly diagnosed MDS patients in comparison to normal/reactive BM (n=29). Our results confirm the existence of heterogeneously altered phenotypes among CD34+ HPC from MDS and indicate that such variability depends both on the relative distribution of the different subsets of CD34+ HPC committed into the different myeloid and B-lymphoid compartments, and their immunophenotype (for example, higher reactivity for CD117 and CD13 and lower expression of CyMPO, CD64 and CD65 on CD34+ immature and neutrophil precursors), a clear association existing between the accumulation of CD34+ HPC and that of immature CD34+ HPC. Interestingly, expansion of erythroid- and neutrophil-lineage CD34+ cells is detected in low-grade MDS at the expense of CD34+ plasmacytoid dendritic cell and B-cell precursors, while expansion of immature CD34+ precursors occurs in high-grade MDS. On the basis of the number and severity of the phenotypic abnormalities detected, a scoring system is proposed that efficiently discriminates between normal/reactive and MDS CD34+ HPC, the mean score significantly increasing from low- to high-grade MDS.

Published
2008

21. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

Author

Hussein, Ma, Vrionis, Fd, Allison, R, Berenson, J, Berven, S, Erdem, E, Giralt, S, Jagannath, S, Kyle, Ra, Legrand, S, Pflugmacher, R, Raje, N, Rajkumar, Sv, Randall, Rl, Roodman, D, Siegel, D, Vescio, R, Zonder, J, Durie, Bg, Alexanian R, International Myeloma Working G. r. o. u. p., Anderson, K, Attal, M, Avet Loiseau, H, Badros, A, Bergsagel, L, Bladé, J, Barlogie, B, Batille, R, Beksac, M, Belch, A, Bensinger, B, Boccadoro, M, Cavo, M, Chen, Wm, Child, T, Chim, J, Comenzo, R, Crowley, J, Dalton, W, Davies, F, de Souza, C, Delforge, M, Dimipoulous, M, Dispenzieri, A, Einsele, H, Facon, T, Fantl, D, Fermand, Jp, Fonseca, R, Gahrton, G, Gertz, M, Gibson, J, Goldschmidt, H, Greipp, P, Hajek, R, Hardan, I, Harousseau, Jl, Hata, H, Hattori, Y, Ho, J, Hungria, V, Hussein, M, Ida, S, Jacobs, P, Jian, H, Joshua, D, Kawano, M, Kumar, S, Kyle, R, Lahuerta, J, Lee, Jh, Lokhorst, H, Ludwig, H, Leleu, X, Maiolino, A, Mehta, J, Merlini, G, Moreau, P, Morgan, G, Munshi, N, Palumbo, Antonio, Pavlovsky, S, Niesvizky, R, Novis, Y, Nouel, A, Powles, R, Pilarski, L, Reece, D, Reiman, T, Richardson, P, Morales, Ar, Sezer, O, Shaughnessy, J, Shimizu, K, Tricot, G, San Miguel, J, Singhal, S, Sonneveld, P, Shustik, C, Spencer, A, Stewart, K, Tosi, P, Turesson, I, Van Ness, B, Van Riet, I, Vesole, D, Waage, A, Wang, M, Weber, D, Westin, J, Wheatley, K, Yehuda, Db, and Zonder, J.

Published
2008

23. 1,000-year environmental history of Lake Issyk-Kul

Author

Giralt, S., Julià, R., Klerkx, J., Riera, S., Leroy, S., Buchaca, T., Catalan, J., De Batist, M., Beck, C., Bobrov, V., Gavshin, V., Kalugin, I., Sukhorukov, F., Brennwald, M., Kipfer, R., Peeters, F., Lombardi, S., Matychenkov, V., Romanovsky, V., Podsetchine, V., and Voltattorni, N.

Published
2004

24. Recent paleoenvironmental evolution of Lake Issyk-kul

Author

Giralt, S., Klerkx, J., Riera, Santiago, Julia, Ramon, Lignier, Vincent, Beck, C., De Batist, Marc, Kalugin, I., Institute of Earth Sciences Jaume Almera, Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Environnements, Dynamiques et Territoires de la Montagne (EDYTEM), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut Pluridisciplinaire Hubert Curien (IPHC), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), RCMG, Universiteit Gent = Ghent University [Belgium] (UGENT), Consejo Superior de Investigaciones Científicas [Spain] (CSIC), and Ghent University [Belgium] (UGENT)

Subjects
[SDE.MCG]Environmental Sciences/Global Changes, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2002

27. Lake Issyk-Kul (Rep. Of Kyrgyzstan) : an example of recent evolution in a continental environment

Author

Giralt, S., Riera, Santiago, Klerkx, J., Julia, Ramon, Lignier, Vincent, Beck, C., De Batist, Marc, Kalugin, I., Institute of Earth Sciences Jaume Almera, Consejo Superior de Investigaciones Científicas [Spain] (CSIC), Environnements, Dynamiques et Territoires de la Montagne (EDYTEM), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut Pluridisciplinaire Hubert Curien (IPHC), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), RCMG, Ghent University [Belgium] (UGENT), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), and Universiteit Gent = Ghent University [Belgium] (UGENT)

Subjects
[SDE.MCG]Environmental Sciences/Global Changes, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2001

28. High-dose chemotherapy - High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia

Author

Anagnostopoulos, A Dimopoulos, MA Aleman, A Weber, D and Alexanian, R Champlin, R Giralt, S

Abstract

Preliminary evidence suggests that high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation may be effective in some patients with resistant Waldenstrom’s macroglobulinemia. During the last 10 years, seven patients with Waldenstrom’s macroglobulinemia have received transplants at the MD Anderson Cancer Center, four with autologous and three with allogeneic stem cells. Four patients achieved partial remission, and three patients have remained alive for at least 2 years. Our data confirm the feasibility of high-dose therapy in patients with macroglobulinemia and support the need for prospective studies of this modality in patients with chemosensitive disease.

Published
2001

37. 1,000-year environmental history of Lake Issyk-Kul

Author

Giralt, S., Julia, R., Klerkx, J., Riera, S., Leroy, S., Buchaca, T., Catalan, J., Marc De Batist, Beck, C., Bobrov, V., Gavshin, V., Kalugin, I., Sukhorukov, F., Brennwald, M., Kipfer, R., Peeters, F., Lombardi, S., Matychenkov, V., Romanovsky, V., Podsetchine, V., Voltattorni, N., Nihoul, Jcj, Zavialov, Po, and Micklin, Pp

42. A phase II trial of peri-transplant palifermin with busulfan, melphalan and fludarabine followed by T-cell depleted hematopoietic stem cell transplants in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) evolved from MDS

Author

Tamari, R., Sheetal, S. R., Deborah Kuk, Papadopoulos, E. B., Jakubowski, A. A., Boulad, F., Small, T. N., Kernan, N. A., Perales, M. A., Koehne, G., Ponce, D. M., Devlin, S., Goldberg, J. D., Young, J. W., Giralt, S. A., O Reilly, R. J., and Castro-Malaspina, H. R.

44. Disease-free survival in adult patients with acute leukemia and advanced CML supports use of double-unit cord blood grafts as an immediate alternative to 8/8 HLA-matched unrelated donors (URD)

Author

Ponce, D. M., Hilden, P., Devlin, S. M., Maloy, M., Lubin, M. N., Castro-Malaspina, H. R., Goldberg, J. D., Jakubowski, A. A., Meagher, R., Papadopoulos, E. B., Perales, M. A., Sauter, C. S., Den Brink, M. R. M., Young, J. W., Nancy Kernan, O Reilly, R. J., Scaradavou, A., Giralt, S., and Barker, J. N.

Catalog

Books, media, physical & digital resources
See catalog results